https://scholars.lib.ntu.edu.tw/handle/123456789/528867
標題: | Severe acute respiratory syndrome epidemic in Taiwan, 2003 | 作者: | PO-REN HSUEH PAN-CHYR YANG |
公開日期: | 2005 | 卷: | 38 | 期: | 2 | 起(迄)頁: | 82-88 | 來源出版物: | Journal of Microbiology, Immunology and Infection | 摘要: | In Taiwan, since the first case of severe acute respiratory syndrome (SARS) was identified on February 25, 2003, a total of 3032 cases of suspected or probable SARS were reported prior to July 5, 2003. Among these cases, 664 cases were classified as probable SARS based on the clinical case definitions and 346 had a positive result for the SARS-associated coronavirus (SARS-CoV). The epidemic in Taiwan could be divided into 2 distinct stages. In stage I (late-February to mid-April) patients had traceable contact with infected patients or travel histories to known affected areas of SARS. By contrast, patients in stage II (mid-April to June) acquired infection via intrahospital or inter-hospital transmission. The mortality rate directly attributable to SARS during the 2 stages of the outbreak in Taiwan was 11% (37 patients). Phylogenetic analysis of sequences of SARS-CoV strains in Taiwan and other countries showed that Taiwanese strains were closely related to those isolated from patients in Hong Kong and Guangdong. The nonspecific initial symptoms and signs of the illness, the absence of reliable diagnostic tests, as well as the initial lack of strict infection control measures in hospitals and effective national control policies contributed to the island-wide spread of the SARS epidemic in Taiwan. Development of an effective strategy to prepare for future outbreaks will require the implementation of an active coordinated clinical reporting system, international collaboration to identify cases in the early stage, development of laboratory tools for early diagnosis, a robust system of prepared isolation, and adequate quarantine facilities. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/528867 | ISSN: | 1684-1182 | SDG/關鍵字: | antivirus agent; corticosteroid; cytokine receptor antagonist; glycyrrhizic acid; immunoglobulin G; immunomodulating agent; interferon; lopinavir; methylprednisolone; prednisolone; ribavirin; adult; age distribution; diagnostic test; disease severity; drug pulse therapy; epidemic; female; health care policy; human; infection control; infection risk; laboratory test; male; mortality; nucleotide sequence; phylogeny; plasma; reliability; review; risk factor; SARS coronavirus; severe acute respiratory syndrome; symptom; Taiwan; travel; virus strain; Adult; Aged; Animals; Antiviral Agents; Communicable Disease Control; Cross Infection; Disease Outbreaks; Disease Reservoirs; Epidemiology, Molecular; Female; Genome, Viral; Humans; Male; Middle Aged; SARS Virus; Severe Acute Respiratory Syndrome; Taiwan |
顯示於: | 醫學院附設醫院 (臺大醫院) |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。